Navigation Links
Two Antioxidant Vitamins Don't Protect Against Heart Disease
Date:11/11/2008

Study highlights:

- A major long-term study of more than 14,000 physicians showed no cardiovascular protection from two antioxidant vitamins taken by much of the American population.

- Taken individually, vitamins E and C failed to protect against heart and blood vessel disease.

NEW ORLEANS, Nov. 11 /PRNewswire-USNewswire/ -- Vitamins E and C -- antioxidant supplements taken by many American adults -- don't protect against cardiovascular disease when taken individually, according to a long-term study of more than 14,000 male physicians presented at the American Heart Association's Scientific Sessions 2008. Results of the Physician's Health Study II (PHS II) were presented as a late-breaking clinical trial. The study was simultaneously published in the Journal of the American Medical Association.

"We found no compelling evidence that either individual vitamin E or vitamin C reduces the risk of cardiovascular disease," said J. Michael Gaziano, M.D., M.P.H., principal investigator of the study and a cardiologist at Brigham and Women's Hospital and VA Boston Healthcare System in Boston, Mass.

Gaziano said results of the study add to the growing consensus about vitamin E's lack of cardiovascular protection based on several earlier trials that failed to find any effect.

The randomized, double-blind, placebo-controlled trial included 14,641 U.S. physicians 50 and older. Cardiovascular disease in the study included nonfatal heart attack, nonfatal stroke and fatal cardiovascular disease

"This is one of the first large-scale, long-term clinical trials of individual vitamin C supplementation in the prevention of cardiovascular disease," said Howard D. Sesso, Sc.D., M.P.H., co-author and project director of PHS II and assistant professor of medicine at Brigham and Women's Hospital.

Unlike several earlier studies in which vitamins E and C were often given as part of an antioxidant cocktail, this study investigated the two vitamins individually, he said.

The findings are an example of the importance of randomized clinical trials to test promising hypotheses generated by laboratory or observational research, Sesso said. Antioxidant vitamins appeared promising in previous laboratory research and in observational human studies, in which people who reported eating a diet rich in vitamins E and C seemed to have fewer cardiovascular problems.

Fruits and vegetables may provide some protective effect beyond the vitamins they contain, or it could be that people who report eating a lot of fruits and vegetables have other characteristics that lead to better health, Sesso said.

Therefore, researchers needed a large, well-designed, placebo-controlled clinical trial -- one that included a dedicated group of participants.

Each year, the investigators mailed participants calendar packs containing each vitamin or its placebo, depending upon the group to which each physician had been randomly assigned. The doses used in the study (400 international units of vitamin E every other day and 500 milligrams of vitamin C daily) correspond to typical amounts available commercially, Gaziano said.

During an average eight years of follow-up, participants provided annual updates on compliance, various risk factors and health outcomes, allowing the investigators access to their medical records when necessary to confirm cardiovascular events or cause of death.

"Broadly speaking, there has been great interest in antioxidants in the prevention of cardiovascular disease," said Sesso. "Despite promising findings from laboratory research and observational studies, our results from PHS II point to the need for large-scale, long-term clinical trials testing the antioxidant hypothesis."

The final arm of PHS II, testing daily multivitamin supplementation, is ongoing.

Individual author disclosures are available on the abstract.

The study was funded by grants from the National Institutes of Health in Bethesda, Md., and an investigator-initiated grant from BASF Corporation in Florham Park, N.J. BASF Corporation, Wyeth Pharmaceuticals in Madison, N.J., and DSM Nutritional Products, Inc., formerly Roche Vitamins, in Parsippany, N.J., provided study agents and packaging.

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at http://www.americanheart.org/corporatefunding.


'/>"/>
SOURCE American Heart Association
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Susan Lark, MD Develops a Powerful ORAC Drink Packed with the Antioxidant Power of Nine Fruits
2. Too Much Sun, Too Few Antioxidants Spell Eye Trouble
3. Sunlight exposure plus low antioxidant levels may place older adults at risk for eye disease
4. Antioxidant-Rich Diet May Protect Against Eye Disease
5. Green Tea Antioxidant May Help Prevent Alzheimers
6. Antioxidant supplements may lessen benefit of radiation and chemotherapy
7. Cancer Patients Should Steer Clear of Antioxidants
8. New Antioxidant Drug Shows Promise Against Diabetes
9. Blueberry Juice Tops The ORAC Antioxidant Chart
10. Determined a new method to establish the antioxidant capacity of extra virgin olive oil
11. Dr. William S. Gruss, M.D., Says That Medical Research Shows You Can Reduce Your Risk of Cancer By Up To 77% and Reverse the Effects of Aging in A CARDIOLOGISTS GUIDE TO ... ANTI-AGING, ANTIOXIDANTS & RESVERATROL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with ... for the primary prevention of cardiovascular diseases during the 15th Annual Women’s ...
(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the Los ... article to the newly revamped Cosmetic Town journal section, featuring articles ... procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi says ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)...  Eli Lilly and Company (NYSE: LLY ... quarter of 2017 on Tuesday, October 24, 2017. Lilly ... with the investment community and media to further detail ... will begin at 9 a.m. Eastern time. Investors, media ... of the conference call through a link that will ...
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology: